A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)

被引：0
作者：
Anders, Carey [1 ]
Le Rhun, Emily [2 ]
Bachelot, Thomas [3 ]
Yardley, Denise [4 ]
Awade, Ahmad [5 ]
Conte, Pierre Franco [6 ]
Cabos, Peter [7 ]
Bear, Melissa [8 ]
Tolaney, Sarah [9 ]
机构：
[1] Duke Canc Inst, Durham, NC USA
[2] Univ Hosp, Lille, France
[3] Ctr Leon Berard, Lyon, France
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Inst Jules Bordet, Brussels, Belgium
[6] Univ Padua, Padua, Italy
[7] Univ Denver, Denver, CO USA
[8] Elli Lilly, Indianapolis, IN USA
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [31] Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study
    Rugo, Hope S.
    Kabos, Peter
    Beck, J. Thad
    Jerusalem, Guy
    Wildiers, Hans
    Sevillano, Elena
    Paz-Ares, Luis
    Chisamore, Michael J.
    Chapman, Sonya C.
    Hossain, Anwar M.
    Chen, Yanyun
    Tolaney, Sara M.
    NPJ BREAST CANCER, 2022, 8 (01)
  • [32] Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
    Hope S. Rugo
    Peter Kabos
    J. Thad Beck
    Guy Jerusalem
    Hans Wildiers
    Elena Sevillano
    Luis Paz-Ares
    Michael J. Chisamore
    Sonya C. Chapman
    Anwar M. Hossain
    Yanyun Chen
    Sara M. Tolaney
    npj Breast Cancer, 8
  • [33] Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2-breast cancer
    Hurvitz, S.
    Martin, M.
    Fernandez Abad, M.
    Chan, D.
    Rostorfer, R.
    Petru, E.
    Barriga, S.
    Costigan, T. M.
    Caldwell, C. W.
    Nguyen, T.
    Press, M.
    Slamo, D.
    CANCER RESEARCH, 2017, 77
  • [34] Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis
    Waks, A. G.
    Gharaibeh, M.
    Sjekloca, N.
    Poluparthi, N.
    Shah, A.
    Bergamaco, E.
    MacCannell, T.
    Leung, G.
    Ntalla, I.
    Oko-osi, H.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S653 - S653
  • [35] POSEIDON randomized phase II trial: Tamoxifen (TAM) plus taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2-metastatic breast cancer (MBC)
    Oliveira, M.
    Baird, R. D.
    Voorthuis, R. A. B.
    De Boo, L.
    van Rossum, A. G. J.
    Cubells, L. Garrigos
    Munoz, S.
    Lopez-Garcia, D.
    Manich, C. Saura
    Schrier, M.
    Mandjes, I.
    Sikorska, K.
    Schot, M.
    Kateb, A.
    Mather, C.
    Beelen, K.
    Cortes, J.
    Caldas, C.
    Linn, S. C.
    ANNALS OF ONCOLOGY, 2021, 32 : S1291 - S1292
  • [36] Real-world study of patients with HR+/ HER2-metastatic breast cancer treated with palbociclib and fulvestrant
    Robert, Nicholas
    Chen, Connie
    Doan, Justin
    Venkatasetty, Divea
    Espirito, Janet L.
    Aguilar, Kathleen M.
    FUTURE ONCOLOGY, 2025, 21 (01) : 83 - 94
  • [37] Real-world patient characteristics, utilization patterns, and outcomes of US patients with HR+/HER2-metastatic breast cancer treated with abemaciclib
    Saverno, Kimberly R.
    Beyrer, Julie
    Smyth, Emily Nash
    Abedtash, Hamad
    DeLuca, Angelo
    Zhu, Yajun Emily
    Rybowski, Sarah
    CANCER RESEARCH, 2021, 81 (04)
  • [38] Everolimus-based combination therapies for HR+, HER2-metastatic breast cancer
    O'Shaughnessy, Joyce
    Beck, J. Thaddeus
    Royce, Melanie
    CANCER TREATMENT REVIEWS, 2018, 69 : 204 - 214
  • [39] VALIDATION OF AN ALGORITHM TO IDENTIFY HR+/HER2-METASTATIC BREAST CANCER IN CLAIMS DATA
    Chin, A.
    Ip, Q.
    Wu, X.
    Lyle, D.
    VALUE IN HEALTH, 2024, 27 (06) : S163 - S163
  • [40] Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2-Metastatic Breast Cancer Treated with Abemaciclib
    Smyth, Emily Nash
    Beyrer, Julie
    Saverno, Kimberly R.
    Hadden, Elizabeth
    Abedtash, Hamed
    DeLuca, Angelo
    Lawrence, Garreth W.
    Rybowski, Sarah
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (04) : 681 - 693
12345